imipramine has been researched along with buspirone in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (14.89) | 18.7374 |
| 1990's | 7 (14.89) | 18.2507 |
| 2000's | 15 (31.91) | 29.6817 |
| 2010's | 17 (36.17) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Bojarski, AJ; Chodkowska, A; Jagiełło-Wójtowicz, E; Kossakowski, J; Kozioł, A; Kuran, B | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bojarski, A; Filipek, B; Jarzyna, M; Marona, H; Pytka, K; Rapacz, A; Sapa, J; Satała, G; Waszkielewicz, AM; Wełna, E; Żmudzki, P | 1 |
| Bojarski, AJ; Bucki, A; Chłoń-Rzepa, G; Jastrzębska-Więsek, M; Kołaczkowski, M; Partyka, A; Satała, G; Wasik, A; Wesołowska, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Handzlik, J; Jankowska, A; Jastrzębska-Więsek, M; Kieć-Kononowicz, K; Kucwaj-Brysz, K; Kurczab, R; Nitek, W; Partyka, A; Satała, G; Siwek, A; Wesołowska, A; Żesławska, E | 1 |
| Bączek, T; Belka, M; Bojarski, A; Herold, F; Kleps, J; Kozioł, AE; Król, M; Nowak, G; Podsadni, P; Siwek, A; Ślifirski, G; Stachowicz, K; Szewczyk, B; Turło, J | 1 |
| Bucki, A; Głuch-Lutwin, M; Jaromin, A; Jastrzębska-Więsek, M; Kołaczkowski, M; Mordyl, B; Partyka, A; Siwek, A; Walczak, M; Wesołowska, A; Zagórska, A | 1 |
| Barrett, JE; Zhang, L | 1 |
| Raj, AB; Sheehan, DV; Sheehan, KH; Soto, S | 2 |
| Hirose, A; Kumasaka, Y; Nakamura, M; Shimizu, H; Tanaka, H; Tatsuno, T | 1 |
| Cahn, W; Kahn, RS; van Praag, HM | 1 |
| Balon, R; Gershon, S; Pohl, R; Yeragani, VK | 1 |
| Chan, TB; Faktor, MI; Korneev, AIa | 1 |
| Howard, JL; Pollard, GT | 1 |
| McNaughton, N; Zhu, XO | 1 |
| Anwyl, R; O'Connor, JJ; Rowan, MJ | 1 |
| Baker, GB; Bateson, AN; Glencorse, TA; Greenshaw, AJ; Tanay, VA | 1 |
| Rickels, K; Schweizer, E | 1 |
| Garcia-España, F; Hassman, H; Rickels, K; Schweizer, E | 1 |
| Carlson, EC; de Felipe, C; Harrison, T; Hunt, S; Oates, B; Owen, S; Rupniak, NM; Seward, E; Wheeldon, A | 1 |
| DeMartinis, N; García-España, F; Greenblatt, DJ; Mandos, LA; Rickels, K; Rynn, M | 1 |
| Ables, AZ; Sontheimer, DL | 1 |
| Baker, GB; Bateson, AN; Greenshaw, AJ; Tanay, VM | 1 |
| Avasthi, A; Gupta, N; Gupta, R | 1 |
| Gorman, JM | 1 |
| García-España, F; Greenblatt, DJ; Mandos, LA; Rickels, K; Rynn, M; Schweizer, E | 1 |
| Nogueira, RL; Zangrossi, H; Zanoveli, JM | 1 |
| Díaz-Ricart, M; Escolar, G; Galán, A; Gastó, C; Gómez-Gil, E; Martín-Santos, R; Martínez De Osaba, MJ; Navinés, R; Salamero, M | 1 |
| Barbui, C; Bighelli, I; Breilmann, J; Castellazzi, M; Cipriani, A; Davies, SJ; Furukawa, TA; Girlanda, F; Guaiana, G; Koesters, M | 1 |
5 review(s) available for imipramine and buspirone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Pathogenesis of panic disorders].
Topics: Adolescent; Adult; Anxiety Disorders; Buspirone; Fear; Female; Humans; Imipramine; Male; Panic | 1989 |
Strategies for treatment of generalized anxiety in the primary care setting.
Topics: Anxiety Disorders; Benzodiazepines; Buspirone; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Humans; Imipramine; Primary Health Care; Psychotherapy; Treatment Outcome | 1997 |
Treating generalized anxiety disorder.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Cognitive Behavioral Therapy; Cyclohexanols; Humans; Imipramine; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2003 |
Benzodiazepines versus placebo for panic disorder in adults.
Topics: Adult; Aged; Agoraphobia; Benzodiazepines; Buspirone; Humans; Imipramine; Middle Aged; Numbers Needed To Treat; Panic Disorder; Paroxetine; Patient Dropouts; Placebos; Propranolol; Randomized Controlled Trials as Topic; Remission Induction; Young Adult | 2019 |
7 trial(s) available for imipramine and buspirone
| Article | Year |
|---|---|
Is buspirone effective for panic disorder?
Topics: Adult; Agoraphobia; Anxiety Disorders; Arousal; Buspirone; Double-Blind Method; Fear; Female; Follow-Up Studies; Humans; Imipramine; Male; Panic; Phobic Disorders; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Single-Blind Method | 1990 |
Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone.
Topics: Adult; Agoraphobia; Brain; Buspirone; Clinical Trials as Topic; Double-Blind Method; Fear; Female; Humans; Imipramine; Male; Panic; Phobic Disorders; Random Allocation; Receptors, Serotonin | 1989 |
The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report.
Topics: Adult; Anxiety Disorders; Buspirone; Fear; Female; Humans; Imipramine; Male; Panic; Placebos | 1988 |
Buspirone and imipramine for the treatment of major depression in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Buspirone; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Geriatric Assessment; Humans; Imipramine; Male; Placebos; Primary Health Care; Psychiatric Status Rating Scales; Serotonin Receptor Agonists; Severity of Illness Index; Treatment Outcome | 1998 |
Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Placebos; Substance Withdrawal Syndrome; Treatment Outcome | 2000 |
Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.
Topics: Adult; Benzodiazepines; Buspirone; Chi-Square Distribution; Double-Blind Method; Female; Follow-Up Studies; Humans; Imipramine; Least-Squares Analysis; Male; Panic Disorder; Prospective Studies | 2003 |
Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment.
Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents, Tricyclic; Buspirone; Depressive Disorder; Diagnostic Techniques, Endocrine; Drug Administration Schedule; Female; Hormones; Humans; Hydrocortisone; Imipramine; Male; Middle Aged; Prolactin; Remission Induction; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Time Factors | 2010 |
35 other study(ies) available for imipramine and buspirone
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Synthesis and serotonin receptor activity of the arylpiperazine alkyl/propoxy derivatives of new azatricycloundecanes.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Mice; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin Receptor Agonists; Structure-Activity Relationship | 2009 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Synthesis and evaluation of antidepressant-like activity of some 4-substituted 1-(2-methoxyphenyl)piperazine derivatives.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Mice; Motor Activity; Piperazines; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin; Rotarod Performance Test; Structure-Activity Relationship | 2015 |
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Mice; Purines; Receptor, Serotonin, 5-HT1A; Structure-Activity Relationship | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
Topics: Animals; Antidepressive Agents; Behavior, Animal; Computer-Aided Design; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Hydantoins; Male; Mice; Models, Molecular; Molecular Structure; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 2018 |
Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
Topics: Animals; Cells, Cultured; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Ligands; Male; Mice; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; RNA-Binding Proteins; Structure-Activity Relationship; Tryptamines | 2019 |
Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia.
Topics: Animals; Antipsychotic Agents; Dementia; Humans; Ligands; Mice; Phosphoric Diester Hydrolases; Serotonin | 2022 |
Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: behavioral studies with pigeons.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Appetitive Behavior; Arousal; Avoidance Learning; Behavior, Animal; Buspirone; Carrier Proteins; Chlordiazepoxide; Color Perception; Columbidae; Conditioning, Classical; Corticotropin-Releasing Hormone; Discrimination Learning; Dose-Response Relationship, Drug; Hypothalamo-Hypophyseal System; Imipramine; Pentobarbital; Peptide Fragments; Pituitary-Adrenal System; Receptors, Drug; Receptors, Neurotransmitter; Reinforcement Schedule | 1990 |
Effects of the putative anxiolytic SM-3997 on central monoaminergic systems.
Topics: Animals; Anti-Anxiety Agents; Biogenic Monoamines; Brain; Brain Chemistry; Buspirone; Dopamine; Imipramine; Isoindoles; Male; Norepinephrine; Piperazines; Pyrimidines; Rats; Rats, Inbred Strains; Serotonin | 1989 |
[Interaction of the anxiolytic agent buspirone with serotonin and other synaptic receptors in the human brain].
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Binding Sites; Brain; Buspirone; Cerebral Cortex; Female; Flunitrazepam; Hippocampus; Humans; Imipramine; In Vitro Techniques; Male; Middle Aged; Pyrimidines; Receptors, Neurotransmitter; Receptors, Serotonin; Strychnine; Tryptamines | 1988 |
Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time greater than 72-s schedule.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Buspirone; Chlorpromazine; Haloperidol; Imipramine; Male; Pyrimidines; Rats; Rats, Inbred Strains; Reinforcement, Psychology; Time Factors | 1986 |
The interaction of serotonin depletion with anxiolytics and antidepressants on reticular-elicited hippocampal RSA.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Buspirone; Cytidine Diphosphate; Drug Interactions; Electric Stimulation; Electroencephalography; Hippocampus; Imipramine; Male; Pindolol; Rats; Rats, Sprague-Dawley; Reticular Formation; Serotonin; Theta Rhythm | 1994 |
Use-dependent effects of acute and chronic treatment with imipramine and buspirone on excitatory synaptic transmission in the rat hippocampus in vivo.
Topics: Animals; Buspirone; Electric Stimulation; Evoked Potentials; Hippocampus; Imipramine; Male; Rats; Rats, Wistar; Serotonin; Synaptic Transmission | 1993 |
Chronic administration of antipanic drugs alters rat brainstem GABAA receptor subunit mRNA levels.
Topics: Animals; Anti-Anxiety Agents; Brain Stem; Buspirone; GABA Agonists; GABA-A Receptor Agonists; Imipramine; Monoamine Oxidase Inhibitors; Neurotransmitter Uptake Inhibitors; Panic Disorder; Phenelzine; Rats; Receptors, GABA-A; RNA, Messenger | 1996 |
Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice.
Topics: Animals; Animals, Newborn; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Buspirone; Diazepam; Dose-Response Relationship, Drug; Female; Fluoxetine; Gene Deletion; Guinea Pigs; Imipramine; Injections, Intraventricular; Male; Mice; Mice, Inbred Strains; Motor Activity; Neurokinin-1 Receptor Antagonists; Peptide Fragments; Piperidines; Receptors, Neurokinin-1; Social Isolation; Stress, Psychological; Substance P; Tetrazoles; Vocalization, Animal | 2000 |
Is imipramine or buspirone treatment effective in patients wishing to discontinue long-term benzodiazepine use?
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Double-Blind Method; Female; Humans; Imipramine; Long-Term Care; Male; Middle Aged; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2001 |
Common effects of chronically administered antipanic drugs on brainstem GABA(A) receptor subunit gene expression.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Brain Stem; Buspirone; Gene Expression Regulation; Imipramine; Infusions, Parenteral; Male; Medulla Oblongata; Phenelzine; Pons; Protein Subunits; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Time Factors | 2001 |
Benzodiazepine discontinuation in generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Humans; Imipramine; Long-Term Care; Substance Withdrawal Syndrome; Treatment Outcome | 2002 |
Chronic imipramine treatment sensitizes 5-HT1A and 5-HT 2 A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Animals; Antidepressive Agents, Tricyclic; Anxiety; Buspirone; Imipramine; Male; Motor Activity; Periaqueductal Gray; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin Receptor Agonists | 2005 |